Asset Details
Do you wish to reserve the book?
Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection
Do you wish to request the book?
Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection
2011
Overview
Background. Antibody to influenza virus hemagglutinin has been traditionally associated with protection. Questions have been raised about its use as a surrogate for vaccine efficacy, particularly with regard to an absolute titer indicating seroprotection. Methods. We examined hemagglutination-inhibition (HAI) antibody titers in subjects from a placebo-controlled trial of inactivated and live attenuated vaccines and compared titers in subjects with symptomatic influenza (cases) to those without influenza infection (noncases). Results. Prevaccination and postvaccination geometric mean titers were both significantly lower for cases compared with noncases in all intervention groups. Frequency of postvaccination seroconversion did not significantly differ for cases and noncases in either vaccine group. Among live attenuated vaccine and placebo recipients, cases were less likely than noncases to have postvaccination HAI titers ≥32 or 64. Nearly all recipients of inactivated vaccine had postvaccination titers of at least 64, and the small number of vaccine failures were scattered across titers ranging from 64 to 2048. Conclusions. While HAI antibody is the major correlate of protection, postvaccination titers alone should not be used as a surrogate for vaccine efficacy. Vaccine failures from clinical trials need to be examined to determine why seemingly protective HAI titers may not protect.
Publisher
Oxford University Press
Subject
/ Adult
/ Biological and medical sciences
/ Female
/ Fundamental and applied biological sciences. Psychology
/ H3N2 subtype influenza A virus
/ Hemagglutination Inhibition Tests
/ Humans
/ Influenza A Virus, H3N2 Subtype - immunology
/ Influenza Vaccines - immunology
/ Influenza, Human - immunology
/ Influenza, Human - prevention & control
/ Male
/ Placebos
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, Attenuated - immunology
/ Vaccines, Inactivated - immunology
/ Viruses
